

June 11, 2025 Nagase & Co., Ltd.

## Capital and Business Alliance Agreement With Craif Inc. —Acquiring Knowledge for Next-generation Business Development

Nagase & Co., Ltd. (Head Office: Chiyoda-ku, Tokyo; Representative Director, President and CEO: Hiroyuki Ueshima), as part of the growth strategy in its Medium-Term Management Plan ACE 2.0, has specified the four quadrants of Foundation, Focus, Development, and Improvement, and is carrying out its businesses along the axes of the trading, manufacturing, and R&D functions. With the goal of building the foundations for next-generation business development and as collaboration in the Development quadrant, Nagase & Co. and Craif Inc. (Head Office: Bunkyo-ku, Tokyo; CEO: Ryuichi Onose) have entered into a capital and business alliance agreement.

This is the first investment through a corporate venture capital (CVC) fund managed and operated by Nagase Future Investments Co., Ltd. (\*1), a wholly owned subsidiary established in April 2025, and represents a first step toward accelerating the use of CVC going forward.

Craif has developed and provides urine testing services that make it possible to detect cancer in very early stages, using a unique technology to analyze the miRNA (microRNA) (\*2) in urine. Their miSignal Scan urine test, which makes it possible to identify with high precision where the cancer has occurred, makes it possible to detect up to seven types of cancer, including pancreatic cancer, which was difficult with previously existing technology. Craif has already provided over 1,000 of these tests to medical facilities and individuals in Japan, and is planning to expand its business to receive certification as a medical device and expand to the US market.

- \*1: <u>Announcement of Establishment of Subsidiary Company and Limited Liability Investment</u>
  Partnership (Transfer of Subsidiary) (Japanese only)
- \*2: Illnesses can change the amount or type of RNA, which controls gene activity, and this can be used to detect cancer early

## **Craif Profile**

· Company Name: Craif Inc.

Head Office: Bunkyo-ku, Tokyo

Representative: CEO Ryuichi Onose

• Business Overview: Research and development of next-generation tests for early detection of illnesses, particularly cancers, and for personalized medicine, and providing miSignal® urinary cancer tests

URL: <a href="https://craif.com/">https://craif.com/</a>

## ■Inquiries

Nagase & Co., Ltd. URL: https://www.nagase.co.jp/english/

<Business Inquiries>

Nagase Future Investments Co., Ltd. Mail : cvc@nagase.co.jp

<Media Inquiries>

PR Section, Corporate Relations Div., Corporate Management Dept., Tel.: 070-4314-0671